Your browser doesn't support javascript.
loading
Expert consensus guidelines for community pharmacists in the management of diabetic peripheral neuropathy with a combination of neurotropic B vitamins.
Sathienluckana, Thanompong; Palapinyo, Sirinoot; Yotsombut, Kitiyot; Wanothayaroj, Ekgaluck; Sithinamsuwan, Pasiri; Suksomboon, Naeti.
Afiliación
  • Sathienluckana T; Faculty of Pharmacy, Siam University, Bangkok, Thailand.
  • Palapinyo S; Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
  • Yotsombut K; Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
  • Wanothayaroj E; Diabetes and Thyroid Center, Theptarin Hospital, Bangkok, Thailand.
  • Sithinamsuwan P; Faculty of Medicine, Phramongkutklao Hospital, Bangkok, Thailand.
  • Suksomboon N; Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
J Pharm Policy Pract ; 17(1): 2306866, 2024.
Article en En | MEDLINE | ID: mdl-38333576
ABSTRACT
This consensus guidance is for community pharmacists in diabetic peripheral neuropathy (DPN) management with a combination of neurotropic B vitamins. A multidisciplinary team including endocrinology, neurology, and pharmacy from Thailand discussed and aligned the practical scheme of DPN management in the community pharmacy setting, using the literature review and having face-to-face meeting. Five major statements have been endorsed as consensus recommendations for DPN care with strong acknowledgment. The aims of DPN management included reducing symptoms and the risk of complications, minimising adverse reactions from treatment regimens, and improving patients' knowledge and adherence to the treatment strategies. An initial screening process using a 7 items interview of Douleur Neuropathique 4 (DN4) questionnaire should be implemented to identify patients at risk of developing DPN. Subsequently, pharmacologic, and non-pharmacologic treatment should be employed based on patient-centered care. An interesting approach is combination of neurotropic B vitamins, which may be used as monotherapy or combination therapy to control DPN symptoms. The combined therapy potentially exhibits a synergistic effect and improves patient adherence. The consensus would be further considered in context of harmonisation of routine practice and country requirements.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Guideline / Qualitative_research Idioma: En Revista: J Pharm Policy Pract Año: 2024 Tipo del documento: Article País de afiliación: Tailandia

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Guideline / Qualitative_research Idioma: En Revista: J Pharm Policy Pract Año: 2024 Tipo del documento: Article País de afiliación: Tailandia